We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
Read MoreHide Full Article
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) ended the recent trading session at $7.63, demonstrating a -1.55% swing from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.33%.
The company's stock has dropped by 6.96% in the past month, falling short of the Medical sector's loss of 3.47% and the S&P 500's gain of 0.41%.
Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$1.27, up 64.72% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $43.92 million, down 20.77% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$6.26 per share and a revenue of $180.84 million, demonstrating changes of +59.87% and -28.08%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ginkgo Bioworks Holdings, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 50.32% upward. Currently, Ginkgo Bioworks Holdings, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 89, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) ended the recent trading session at $7.63, demonstrating a -1.55% swing from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.33%.
The company's stock has dropped by 6.96% in the past month, falling short of the Medical sector's loss of 3.47% and the S&P 500's gain of 0.41%.
Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$1.27, up 64.72% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $43.92 million, down 20.77% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$6.26 per share and a revenue of $180.84 million, demonstrating changes of +59.87% and -28.08%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ginkgo Bioworks Holdings, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 50.32% upward. Currently, Ginkgo Bioworks Holdings, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 89, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.